BioXcel Therapeutics (BTAI) Stock Forecast, Price Target & Predictions
BTAI Stock Forecast
BioXcel Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a 2011.56% upside from BTAI’s last price of $0.57) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
BTAI Price Target
The average price target for BioXcel Therapeutics (BTAI) is $12.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $1.00. This represents a potential 2011.56% upside from BTAI's last price of $0.57.
BTAI Analyst Ratings
According to 8 Wall Street analysts, BioXcel Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BTAI stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BioXcel Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Graig Suvannavejh | Mizuho Securities | $1.00 | $0.59 | 69.81% | 75.96% |
| Apr 15, 2024 | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $2.90 | 244.83% | 1659.63% |
| Aug 15, 2023 | Graig Suvannavejh | Mizuho Securities | $4.00 | $3.98 | 0.63% | 603.85% |
| Jan 03, 2023 | - | H.C. Wainwright | $73.00 | $21.48 | 239.85% | 12745.33% |
| Nov 11, 2022 | - | Guggenheim | $25.00 | $14.82 | 68.69% | 4299.08% |
The latest BioXcel Therapeutics stock forecast, released on Sep 23, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $1.00, which represents a 69.81% increase from the stock price at the time of the forecast ($0.59), and a 75.96% increase from BTAI last price ($0.57).
BioXcel Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $1.00 | $5.50 |
| Last Closing Price | $0.57 | $0.57 | $0.57 |
| Upside/Downside | -100.00% | 75.96% | 867.80% |
In the current month, the average price target of BioXcel Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioXcel Therapeutics's last price of $0.57. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 15, 2023 | Wells Fargo | Buy | Buy | Hold |
| May 26, 2023 | Goldman Sachs | Neutral | Neutral | Hold |
| Mar 21, 2023 | Piper Sandler | Buy | Buy | Hold |
| Mar 10, 2023 | Oppenheimer | - | Outperform | Initialise |
| Mar 10, 2023 | JonesTrading | - | Buy | Initialise |
| Mar 10, 2023 | Maxim Group | - | Buy | Initialise |
| Dec 01, 2022 | Goldman Sachs | - | Neutral | Upgrade |
BioXcel Therapeutics's last stock rating was published by H.C. Wainwright on Oct 21, 2024. The company gave BTAI a "Buy" rating, the same as its previous rate.
BioXcel Therapeutics Financial Forecast
BioXcel Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $376.00K | - | - | $206.00K | $238.00K | $137.00K | - | - |
| Avg Forecast | $1.70M | $1.50M | $1.40M | $1.30M | $1.27M | $1.33M | $762.50K | $450.00K | $742.86K | $626.00K | $453.89K | $389.00K | $1.08M | $1.00M | $125.00K | $9.90K |
| High Forecast | $1.94M | $1.71M | $1.60M | $1.48M | $1.44M | $1.37M | $762.75K | $512.71K | $1.27M | $628.00K | $517.14K | $443.20K | $1.23M | $1.00M | $125.00K | $11.88K |
| Low Forecast | $1.50M | $1.32M | $1.23M | $1.15M | $1.12M | $1.29M | $762.25K | $396.90K | $317.46K | $624.00K | $400.33K | $343.10K | $952.40K | $1.00M | $125.00K | $7.92K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | 0.51% | - | - | 0.53% | 0.22% | 0.14% | - | - |
BioXcel Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $450.00K, with a low forecast of $396.90K, and a high forecast of $512.71K. BTAI's average Quarter revenue forecast represents a 19.68% increase compared to the company's last Quarter revenue of $376.00K (Dec 23).
BioXcel Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | $-19.88M | - | - | $-49.43M | $-51.89M | $-38.99M | $-31.39M | $-26.30M |
| Avg Forecast | $340.00K | $300.00K | $280.00K | $260.00K | $253.38K | $265.52K | $152.50K | $90.00K | $148.57K | $125.20K | $90.78K | $77.80K | $215.96K | $200.96K | $-32.21M | $-22.39M |
| High Forecast | $387.38K | $341.80K | $319.02K | $296.23K | $288.69K | $273.38K | $152.55K | $102.54K | $253.97K | $125.60K | $103.43K | $88.64K | $246.06K | $200.96K | $-25.77M | $-17.91M |
| Low Forecast | $299.88K | $264.60K | $246.96K | $229.32K | $223.48K | $257.66K | $152.45K | $79.38K | $63.49K | $124.80K | $80.06K | $68.62K | $190.48K | $200.96K | $-38.65M | $-26.86M |
| Surprise % | - | - | - | - | - | - | - | - | -133.77% | - | - | -635.34% | -240.26% | -194.02% | 0.97% | 1.18% |
undefined analysts predict BTAI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than BioXcel Therapeutics's previous annual EBITDA (undefined) of $NaN.
BioXcel Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| Net Income | - | - | - | - | - | - | - | - | $-22.26M | - | - | $-51.03M | $-58.09M | $-44.62M | $-31.46M | $-26.38M |
| Avg Forecast | $-11.87M | $-16.53M | $-19.08M | $-19.08M | $-16.53M | $-21.43M | $-30.21M | $-28.61M | $-38.86M | $-54.00M | $-73.90M | $-68.61M | $-60.29M | $-52.77M | $-32.29M | $-22.45M |
| High Forecast | $-10.05M | $-14.00M | $-16.15M | $-16.15M | $-14.00M | $-18.14M | $-25.57M | $-24.22M | $-26.57M | $-45.72M | $-62.56M | $-58.09M | $-51.04M | $-52.77M | $-25.83M | $-17.96M |
| Low Forecast | $-14.02M | $-19.53M | $-22.53M | $-22.53M | $-19.53M | $-25.31M | $-35.68M | $-33.79M | $-48.77M | $-63.78M | $-87.29M | $-81.04M | $-71.21M | $-52.77M | $-38.75M | $-26.94M |
| Surprise % | - | - | - | - | - | - | - | - | 0.57% | - | - | 0.74% | 0.96% | 0.85% | 0.97% | 1.18% |
BioXcel Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BTAI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
BioXcel Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| SG&A | - | - | - | - | - | - | - | - | $9.60M | - | - | $23.59M | $20.66M | $17.05M | $12.92M | $11.64M |
| Avg Forecast | $83.91M | $74.04M | $69.11M | $64.17M | $62.54M | $65.53M | $37.64M | $22.21M | $36.67M | $30.90M | $22.40M | $19.20M | $53.30M | $49.57M | $6.17M | $488.57K |
| High Forecast | $95.61M | $84.36M | $78.74M | $73.11M | $71.25M | $67.47M | $37.65M | $25.31M | $62.68M | $31.00M | $25.53M | $21.88M | $60.73M | $49.57M | $6.17M | $586.25K |
| Low Forecast | $74.01M | $65.30M | $60.95M | $56.60M | $55.16M | $63.59M | $37.63M | $19.59M | $15.67M | $30.80M | $19.76M | $16.94M | $47.01M | $49.57M | $6.17M | $390.85K |
| Surprise % | - | - | - | - | - | - | - | - | 0.26% | - | - | 1.23% | 0.39% | 0.34% | 2.10% | 23.82% |
BioXcel Therapeutics's average Quarter SG&A projection for Mar 24 is $22.21M, based on 4 Wall Street analysts, with a range of $19.59M to $25.31M. The forecast indicates a 131.31% rise compared to BTAI last annual SG&A of $9.60M (Dec 23).
BioXcel Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| EPS | - | - | - | - | - | - | - | - | $-0.76 | - | - | $-1.78 | $-2.07 | $-1.59 | $-1.12 | $-1.08 |
| Avg Forecast | $-0.28 | $-0.39 | $-0.45 | $-0.45 | $-0.39 | $-0.51 | $-0.71 | $-0.67 | $-0.92 | $-1.27 | $-1.74 | $-1.62 | $-1.42 | $-1.31 | $-1.10 | $-0.95 |
| High Forecast | $-0.24 | $-0.33 | $-0.38 | $-0.38 | $-0.33 | $-0.43 | $-0.60 | $-0.57 | $-0.63 | $-1.08 | $-1.48 | $-1.37 | $-1.20 | $-1.31 | $-1.10 | $-0.95 |
| Low Forecast | $-0.33 | $-0.46 | $-0.53 | $-0.53 | $-0.46 | $-0.60 | $-0.84 | $-0.80 | $-1.15 | $-1.50 | $-2.06 | $-1.91 | $-1.68 | $-1.31 | $-1.10 | $-0.95 |
| Surprise % | - | - | - | - | - | - | - | - | 0.83% | - | - | 1.10% | 1.46% | 1.21% | 1.02% | 1.13% |
According to undefined Wall Street analysts, BioXcel Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BTAI previous annual EPS of $NaN (undefined).
BioXcel Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.68 | $70.00 | 10194.12% | Buy |
| BTAI | BioXcel Therapeutics | $0.57 | $12.00 | 2005.26% | Buy |
| ELEV | Elevation Oncology | $0.53 | $9.00 | 1598.11% | Buy |
| XFOR | X4 Pharmaceuticals | $0.40 | $3.67 | 817.50% | Buy |
| INZY | Inozyme Pharma | $3.13 | $14.67 | 368.69% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.40 | $7.00 | 191.67% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| TERN | Terns Pharmaceuticals | $6.17 | $14.25 | 130.96% | Buy |
| VKTX | Viking Therapeutics | $49.58 | $102.40 | 106.53% | Buy |
| MREO | Mereo BioPharma Group | $3.53 | $6.75 | 91.22% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.76 | $5.33 | 11.97% | Buy |
| MDGL | Madrigal Pharmaceuticals | $288.58 | $315.75 | 9.42% | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
| TGTX | TG Therapeutics | $29.54 | $27.60 | -6.57% | Buy |
| EXEL | Exelixis | $34.45 | $30.50 | -11.47% | Buy |